CẬP NHẬT CHẨN ĐOÁN VÀ ĐIỀU TRỊ SUY TỦY XƯƠNG MẮC PHẢI VÔ CĂN

Acquired idiopathic aplastic anemia (AA) is a rare, life-threatening condition characterized by the immune-mediated destruction of hematopoietic stem cells. It manifests as peripheral blood cytopenia affecting at least two lineages alongside a hypocellular bone marrow. Despite therapeutic advances, clinical practice variations persist regarding diagnosis and optimal management. AA remains a diagnosis of exclusion, focusing on: (i) confirming marrow hypocellularity via aspirate and trephine biopsy; (ii) excluding malignancies, hypocellular myelodysplastic syndrome (hMDS), marrow infiltration, and secondary causes (infections/drugs/chemicals); and (iii) screening for inherited bone marrow failure (IBMF) in younger patients or those with suggestive clinical/family histories.Recent international guidelines emphasize expanded diagnostic workups before initiating definitive therapy, including flow cytometry for PNH clones, somatic mutation screening (myeloid panels), and telomere length measurement—particularly in severe, very severe, or refractory cases. Early HLA typing is critical for potential transplant candidates.Treatment rests on two pillars: allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST). Current BSH 2024 and ASH 2026 guidelines state that initial choice depends on disease severity (modified Camitta criteria), biological age, and donor availability. The modern standard IST for severe AA in non-transplant candidates is the triple combination of hATG, cyclosporine and eltrombopag, supported by the phase III RACE trial data. Complication management must be integrated early, focusing on leukodepleted/irradiated blood products, antimicrobial prophylaxis (anti-mold) when ANC < 0.5 × 10⁹/L, and monitoring for iron overload or clonal evolution via periodic cytogenetics.Key evidence gaps remain in optimizing alternative donor transplants (MUD/haplo), personalized NGS-based strategies, and the long-term safety of TPO-RAs regarding clonal progression and thrombosis.

Authors

Publication Details

Journal
Journal of Clinical Medicine Bach Mai Hospital
Published
2026-11-21
DOI
https://doi.org/10.52322/jocmbmh.156.0302
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CẬP NHẬT CHẨN ĐOÁN VÀ ĐIỀU TRỊ SUY TỦY XƯƠNG MẮC PHẢI VÔ CĂN

Thiện Ngôn Huỳnh
Journal of Clinical Medicine Bach Mai Hospital
Blood disorders and treatments
article

CẬP NHẬT CHẨN ĐOÁN VÀ ĐIỀU TRỊ SUY TỦY XƯƠNG MẮC PHẢI VÔ CĂN

Thiện Ngôn Huỳnh
article en

Abstract

Acquired idiopathic aplastic anemia (AA) is a rare, life-threatening condition characterized by the immune-mediated destruction of hematopoietic stem cells. It manifests as peripheral blood cytopenia affecting at least two lineages alongside a hypocellular bone marrow. Despite therapeutic advances, clinical practice variations persist regarding diagnosis and optimal management. AA remains a diagnosis of exclusion, focusing on: (i) confirming marrow hypocellularity via aspirate and trephine biopsy; (ii) excluding malignancies, hypocellular myelodysplastic syndrome (hMDS), marrow infiltration, and secondary causes (infections/drugs/chemicals); and (iii) screening for inherited bone marrow failure (IBMF) in younger patients or those with suggestive clinical/family histories.Recent international guidelines emphasize expanded diagnostic workups before initiating definitive therapy, including flow cytometry for PNH clones, somatic mutation screening (myeloid panels), and telomere length measurement—particularly in severe, very severe, or refractory cases. Early HLA typing is critical for potential transplant candidates.Treatment rests on two pillars: allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST). Current BSH 2024 and ASH 2026 guidelines state that initial choice depends on disease severity (modified Camitta criteria), biological age, and donor availability. The modern standard IST for severe AA in non-transplant candidates is the triple combination of hATG, cyclosporine and eltrombopag, supported by the phase III RACE trial data. Complication management must be integrated early, focusing on leukodepleted/irradiated blood products, antimicrobial prophylaxis (anti-mold) when ANC < 0.5 × 10⁹/L, and monitoring for iron overload or clonal evolution via periodic cytogenetics.Key evidence gaps remain in optimizing alternative donor transplants (MUD/haplo), personalized NGS-based strategies, and the long-term safety of TPO-RAs regarding clonal progression and thrombosis.

Journal of Clinical Medicine Bach Mai HospitalVol. 3(156)
Blood disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon